Nabriva Therapeutics Earnings, Revenue Miss in Q1
- ByInvesting.com-
Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Thursday first quarter earnings that missed analysts' forecasts and revenue that fell short of...
Symbol | Exchange | Currency |
|---|
Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Thursday first quarter earnings that missed analysts' forecasts and revenue that fell short of...
Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Tuesday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Nabriva...
Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations. Nabriva...
Nabriva (NASDAQ:NBRV) Therapeuticsplc NBRV has been struggling lately, but the selling pressure may be coming to an end soon. That is because NBRV recently saw a Hammer Chart...
Axsome Therapeutics (NASDAQ:AXSM), Inc. AXSM incurred a loss of 78 cents per share in the fourth quarter of 2020, wider than the Zacks Consensus Estimate of a loss of 73 cents per...
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced that it has completed patient enrollment in the phase III ILLUMINATE-301 study, evaluating tilsotolimod in combination with...
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 93.79 | 95.91 | 91.48 | -0.57 | -0.60% | 3.84M | NYSE | |||
| 209.96 | 218.44 | 206.35 | -5.07 | -2.36% | 386.14K | NYSE | |||
| 39.49 | 39.79 | 38.20 | +0.36 | +0.92% | 751.13K | NASDAQ | |||
| 17.07 | 17.17 | 16.78 | +0.08 | +0.47% | 2.87M | NYSE | |||
| 485.73 | 487.47 | 472.31 | +7.18 | +1.50% | 2.99M | NYSE | |||
| 86.79 | 90.17 | 84.73 | -0.90 | -1.03% | 21.02M | NYSE | |||
| 0.36 | 0.36 | 0.36 | -0.015 | -4.03% | 18.12K | OTC Markets | |||
| 5.57 | 5.57 | 5.57 | -0.41 | -6.85% | 147.00 | OTC Markets | |||
| 5.00 | 5.00 | 5.00 | 0 | 0.00% | 0.00 | OTC Markets | |||
| 1.42 | 1.68 | 1.42 | -0.200 | -12.35% | 74.91K | NASDAQ | |||
| 0.92 | 0.95 | 0.88 | 0.00 | +0.51% | 376.92K | NASDAQ | |||
| 3.08 | 3.08 | 3.08 | +0.105 | +3.53% | 72.00 | OTC Markets | |||
| 13.79 | 13.79 | 13.79 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 3.46 | 3.46 | 3.46 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 2.01 | 2.01 | 2.01 | 0.0000 | 0.00% | 0.00 | OTC Markets |